0 Replies
... Nucleotide rnas termed sirnas that are used in a sequence-specific manner to recognize and destroy complementary rna. The report compares rnai with other antisense approaches using oligonucleotides, aptamers ... Contine Reading & Discuss→
0 Replies
LAKE OSWEGO, Ore., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will provide a presentation entitled, "Advancing Personalized... Contine Reading & Discuss→
0 Replies
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that the United
States Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for patent application number 12/813,448, covering the
company’s proprietary second generation lipid nanoparticle (LNP)
platform, including the “MC3†lipid. This second generation LNP... Contine Reading & Discuss→
0 Replies
Scientists report on the discovery of a protein expression feedback mechanism that may explain why the BRAF inhibitor vemurafenib (PLX4032) is an effective therapy for melanomas carrying the BRAF V600E mutation but is much less effective against colon cancers carrying exactly the same mutation. A team led by scientists at... Contine Reading & Discuss→
